<DOC>
	<DOC>NCT02453672</DOC>
	<brief_summary>Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab</brief_summary>
	<brief_title>Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects</brief_title>
	<detailed_description>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Healthy male subjects Have body weight between 65.090.0 kg (inclusive) and body mass index between 20.029.9 kg/m2 (inclusive) Have a history of hypersensitivity or allergic reactions to bevacizumab or to any of the excipients Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric, or allergic disease excluding mild asymptomatic seasonal allergies Have a history of arterial thromboembolic events including cerebrovascular accidents, transient ischaemic attacks, and myocardial infarction Have a history of and/or current cardiac disease Have previously been exposed to vascular endothelial growth factor (VEGF) antibody, any other antibody, or protein targeting the VEGF receptor Have a history of cancer including lymphoma, leukaemia, and skin cancer. Have received live vaccine(s) within 30 days prior to Screening visit or who will require a vaccine(s) between Screening and the end of study visit Have taken medication with a halflife of &gt; 24 hours within 30 days or 10 halflives of the medication prior to the IP administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>